A phase II study of doxorubicin and cisplatin combination chemotherapy for advanced hepatocellular carcinoma.
- Author:
Bo Lee KANG
1
;
Young Jin YUH
;
Sung Rok KIM
;
Hong Suk SONG
;
Soon Nam LEE
;
Dong Bok SHIN
;
Myung Ju AHN
;
Yeon Hee PARK
Author Information
1. Department of Internal Medicine, Sanggye paik hospital, Inje University College of Medicine, Seoul, Korea. sungrkim@sanggyepaik.ac.kr
- Publication Type:Original Article
- Keywords:
Hepatocellular carcinoma;
Doxorubicin;
Cisplatin
- MeSH:
Bilirubin;
Bone Marrow;
Carcinoma, Hepatocellular*;
Cisplatin*;
Doxorubicin*;
Drug Therapy;
Drug Therapy, Combination*;
Humans;
Liver Cirrhosis;
Neutropenia;
Prospective Studies;
Thrombocytopenia
- From:Korean Journal of Medicine
2005;68(2):203-210
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: There still is no standard treatment for the patients with advanced hepatocellular carcinoma. Both doxorubicin and cisplatin have modest activity with the response rates less than 20%, but have synergistic effect. This prospective phase II trial was performed to determine the efficacy and toxicity of doxorubicin and cisplatin combination chemotherapy for patients with advanced hepatocellular carcinoma. METHODS: Patients with advanced hepatocellular carcinoma were entered into this study. Eligibility criteria are described below: histologically proven HCC or mass lesion on radiogram with liver cirrhosis and serum a-fetoprotein level >or=400 ng/mL, UICC stage IV, recurred after any loco-regional treatment, no prior cytotoxic chemotherapy, measurable disease, ECOG performance scale 0~2, age 18~65 year old, adequate bone marrow, cardiac and renal function, total bilirubin
